Pharmacogenetic testing
Pharmacogenetic testing (for example GeneSight) uses a DNA sample to report how your genes may affect the way your body handles psychiatric medications. What a report predicts is a gene and drug interaction, not whether a medication will make you feel better. Studies so far show a small benefit at most, and testing is not part of routine care in most guidelines. It may be most useful for people who have had side effects on several medicines.
Also called: GeneSight test, GeneSight, Pharmacogenomic testing.
Written by Alena Kozlova, PhD, from published studies and prescribing information.
Definition medically reviewed by Dr. Jason Tan, Consultant Psychiatrist, on November 11, 2026, this definition only. Next review: November 11, 2027.
What does a pharmacogenetic test tell you?
Report formats differ between tests. A GeneSight report sorts antidepressants into groups. In GUIDED, the trial that tested this kind of report, the groups were use as directed, use with caution, and use with increased caution and with more frequent monitoring. The genes behind those groups are mostly liver enzymes, such as CYP2C19, that break a drug down.
That effect on drug levels is measurable. The US label for Celexa reports that in CYP2C19 poor metabolizers the same citalopram dose leaves roughly twice as much drug in the body at steady state, with peak levels up 68% and total exposure up 107%, and it caps the maximum daily dose lower for them. So your genes can change how much drug you end up with, which is a different question from which antidepressant suits your depression.
Does pharmacogenetic testing help you find the right antidepressant?
A little, in the trials that tested it. GUIDED, published in 2019, randomized 1,167 outpatients whose depression had not responded well to at least one earlier antidepressant to guided care or treatment as usual. Several of its authors worked for Assurex Health and Myriad Genetics, the company that sells GeneSight. The depression score fell by 27.2% on average with guided care against 24.4% in usual care, a difference that was not significant (p = 0.107). The share of people who responded, meaning their score at least halved, was 26.0% against 19.9% (p = 0.013), and remission 15.3% against 10.1% (p = 0.007).
The larger trial since then found less, in different people. PRIME Care randomized 1,944 patients across 676 clinicians at 22 VA medical centers who were starting or switching to a single antidepressant, rather than people for whom earlier treatment had already failed, and its report names only a commercial pharmacogenomic test, without the brand. Testing did change prescribing: 59.3% of the test group got a medication with no predicted gene and drug interaction, against 25.7% in usual care. Remission over 24 weeks was higher by 2.8% (odds ratio 1.28, p = 0.02), and by week 24 the two groups were no different (p = 0.45). Its authors call the effects on remission small and nonpersistent.
A 2026 systematic review pooled the three trials of GeneSight itself and found response about 1.3 times as likely with guided care (risk ratio 1.30) and remission about 1.5 times as likely (risk ratio 1.53), measured in a window of 8 to 12 weeks. Its authors call that evidence limited, a small number of short trials with some risk of bias, and across the other testing platforms the pooled result was no better than usual care.
What do US labels say about your genes?
Some name a gene, none ask for a test. The Celexa label caps the maximum daily dose lower for CYP2C19 poor metabolizers, as it does for people over 60 and people with liver problems, and the Lexapro label mentions CYP2C19 only when comparing drug levels. Neither tells a prescriber to test you first.
So a gene result can matter for how high a dose goes. Which antidepressant to try is still a judgement your prescriber makes from your history, your other medicines and what happened last time.
Should you pay for a pharmacogenetic test?
Work that out with your prescriber before you order it. Ask what they would do differently with the result, whether your plan would look different without it, what your insurance covers, and what it would mean for the medication you are on now.
A test cannot replace the other record that guides a switch: which antidepressants you have taken, how high the dose went, how long you stayed there and what it did to you. Bring that list to the appointment, with the highest dose you reached and what each one felt like. It is usually the stronger evidence, and it is the part you can put together yourself.
What to do
Talk a test over with your prescriber before you order one, and bring your own record of the antidepressants you have taken, the doses and what each one felt like. If a report makes you want to stop or switch, raise it at the appointment rather than acting on it yourself. If your mood drops while you wait, tell your prescriber. If you’re having thoughts of harming yourself, contact emergency services or a crisis line straight away. In the US, call or text 988. In the UK, call Samaritans on 116 123. Elsewhere, find a crisis line near you.
How switching antidepressants works
How withClaro helps
- Log how you feel each day, next to the dose you took
- Share a PDF report with your prescriber before the appointment
- Reminders, so a trial is not cut short by missed doses
Get the withClaro app on the App Store
Related terms
Sources
- Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechairo B. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. Journal of Psychiatric Research, 2019.
- Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, Kranzler HR, Gelernter J, Pyne JM. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA, 2022.
- Pullano I, Iazzolino AM, Di Lorenzo C, Monaco F, Miola A, Fornaro M, Steardo L Jr. Clinical effectiveness of pharmacogenomic-guided antidepressant treatment in adult major depressive disorder: systematic review and exploratory platform-aware meta-analysis. Journal of Psychiatric Research, 2026.
- U.S. Food and Drug Administration. Celexa (citalopram): prescribing information. FDA / DailyMed, 2023.
- U.S. Food and Drug Administration. Lexapro (escitalopram) tablets and oral solution: prescribing information. FDA / DailyMed, 2026.
All glossary terms